{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:00:51Z","timestamp":1790031651437,"version":"4.0.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"S33","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Proc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The HPV Prevention and Control Board convened its 18th technical meeting in Antwerp, Belgium (June 2025) to review the evidence on universal HPV vaccination and the role of anal cancer screening in the elimination of HPV-associated cancers. While HPV prevention has historically focused on cervical cancer in women, growing evidence supports extending both primary and secondary prevention to male cohorts and non-cervical anatomical sites. HPV causes approximately 148,072 cancer cases in men annually in the world \u2014 likely a substantial undercount \u2014 affecting primarily the oropharynx, anus, and penis. Men's lower seroconversion rates after natural HPV infection and sustained HPV prevalence across age groups makes vaccination an essential tool to prevent HPV-related disease in this population. Community-randomised trial evidence confirms that universal vaccination delivers stronger herd protection than girls-only strategies and may accelerate elimination of the most oncogenic types within 15\u201330\u00a0years. While modelling analyses identify high coverage in girls as the most efficient strategy for cervical cancer elimination, universal vaccination is justified on broader public health grounds, including equity, programme resilience, reduced vaccine hesitancy, and prevention of non-cervical cancers. Country experiences from Scotland and Cameroon highlight persistent equity gaps and the critical role of community engagement. Given the direct epidemiological link between HPV infection in males \u2014 particularly gay, bisexual, and other men who have sex with men and immunocompromised populations, such as people living with HIV \u2014 and anal cancer risk, the meeting identified anal cancer screening as the most advanced non-cervical secondary prevention strategy warranting immediate attention. The ANCHOR trial demonstrated that treating anal high-grade squamous intraepithelial lesions reduces anal cancer incidence by 57%. Despite the publication of the first evidence-based U.S. Health and Human Services and International Anal Neoplasia Society guidelines in 2024, implementation remains constrained by high-resolution anoscopy capacity, workforce shortages, stigma, and limited evidence on optimal screening algorithms. The meeting concluded that integrating universal vaccination with targeted anal cancer screening \u2014 supported by equitable access, biomarker development, and living guidelines that evolve with emerging evidence \u2014 is essential to reducing HPV-related cancer burden in both women and men.<\/jats:p>","DOI":"10.1186\/s12919-026-00393-1","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:03:12Z","timestamp":1790028192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elimination of HPV-associated cancers: universal HPV vaccination and the role of anal screening \u2013 a meeting report"],"prefix":"10.1186","volume":"20","author":[{"given":"F. Ricardo","family":"Burdier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly R.","family":"Mugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Palefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann N.","family":"Burchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Roelandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Baay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Baussano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dur-e-Nayab","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Vorsters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"393_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pvr.2017.07.001","volume":"4","author":"A Vorsters","year":"2017","unstructured":"Vorsters A, Arbyn M, Baay M, Bosch X, de Sanjose S, Hanley S, et al. Overcoming barriers in HPV vaccination and screening programs. Papillomavirus Res. 2017;4:45\u201353.","journal-title":"Papillomavirus Res"},{"key":"393_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100183","volume":"8","author":"A Vorsters","year":"2019","unstructured":"Vorsters A, Bonanni P, Maltezou HC, Yarwood J, Brewer NT, Bosch FX, et al. The role of healthcare providers in HPV vaccination programs - A meeting report. Papillomavirus research (Amsterdam, Netherlands). 2019;8:100183.","journal-title":"Papillomavirus research (Amsterdam, Netherlands)"},{"issue":"7","key":"393_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12919-021-00217-4","volume":"15","author":"DE Waheed","year":"2021","unstructured":"Waheed DE, Schiller J, Stanley M, Franco EL, Poljak M, Kjaer SK, et al. Human papillomavirus vaccination in adults: impact, opportunities and challenges \u2013 a meeting report. BMC Proc. 2021;15(7):16.","journal-title":"BMC Proc"},{"key":"393_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102368","volume":"35","author":"DE Waheed","year":"2023","unstructured":"Waheed DE, Burdier FR, Eklund C, Baussano I, Mariz FC, T\u00e9blick L, et al. An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report. Prev Med Rep. 2023;35:102368.","journal-title":"Prev Med Rep"},{"key":"393_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2024.102678","volume":"41","author":"FR Burdier","year":"2024","unstructured":"Burdier FR, Waheed DE, Nedjai B, Steenbergen RDM, Poljak M, Baay M, et al. DNA methylation as a triage tool for cervical cancer screening - A meeting report. Prev Med Rep. 2024;41:102678.","journal-title":"Prev Med Rep"},{"issue":"Suppl 9","key":"393_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12919-020-00192-2","volume":"14","author":"A Vorsters","year":"2020","unstructured":"Vorsters A, Bosch FX, Bonanni P, Franco EL, Baay M, Simas C, et al. Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report. BMC Proc. 2020;14(Suppl 9):8.","journal-title":"BMC Proc"},{"issue":"Suppl 11","key":"393_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12919-023-00271-0","volume":"17","author":"DE Waheed","year":"2023","unstructured":"Waheed DE, Olivier CW, Riethmuller D, Franco EL, Pr\u00e9tet JL, Baay M, et al. Prevention and control of HPV and HPV-related cancers in France: the evolving landscape and the way forward - a meeting report. BMC Proc. 2023;17(Suppl 11):18.","journal-title":"BMC Proc"},{"issue":"4","key":"393_CR8","first-page":"189","volume":"33","author":"A Nowakowski","year":"2024","unstructured":"Nowakowski A, Prusaczyk A, Szenborn L, Ludwikowska K, Paradowska-Stankiewicz I, Machalek DA, et al. The HPV prevention and control program in Poland: progress and the way forward. Acta Dermatovenerol Alp Pannonica Adriat. 2024;33(4):189\u201397.","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"3","key":"393_CR9","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 5","key":"393_CR10","doi-asserted-by":"publisher","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","volume":"30","author":"D Forman","year":"2012","unstructured":"Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-23.","journal-title":"Vaccine"},{"issue":"4","key":"393_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664\u201370.","journal-title":"Int J Cancer"},{"issue":"12","key":"393_CR12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1470-2045(14)70471-1","volume":"15","author":"C Ndiaye","year":"2014","unstructured":"Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagu\u00e9 X, Laporte L, et al. HPV DNA, E6\/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319\u201331.","journal-title":"Lancet Oncol"},{"issue":"3","key":"393_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/PPO.0000000000000115","volume":"21","author":"AP Stein","year":"2015","unstructured":"Stein AP, Saha S, Kraninger JL, Swick AD, Yu M, Lambert PF, et al. Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. Cancer J. 2015;21(3):138\u201346.","journal-title":"Cancer J"},{"issue":"12","key":"393_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1080\/00016489.2019.1669820","volume":"139","author":"KD Stjernstr\u00f8m","year":"2019","unstructured":"Stjernstr\u00f8m KD, Jensen JS, Jakobsen KK, Gr\u00f8nh\u00f8j C, von Buchwald C. Current status of human papillomavirus positivity in oropharyngeal squamous cell carcinoma in Europe: a systematic review. Acta Otolaryngol. 2019;139(12):1112\u20136.","journal-title":"Acta Otolaryngol"},{"issue":"2","key":"393_CR15","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2018","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2018;8(2):e180\u201390.","journal-title":"Lancet Glob Health"},{"issue":"36","key":"393_CR16","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1200\/JCO.2013.50.3870","volume":"31","author":"AK Chaturvedi","year":"2013","unstructured":"Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"393_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jamaoto.2021.3567","volume":"148","author":"H Damgacioglu","year":"2001","unstructured":"Damgacioglu H, Sonawane K, Zhu Y, Li R, Balasubramanian BA, Lairson DR, et al. Oropharyngeal cancer incidence and mortality trends in all 50 states in the US, 2001-2017. JAMA Otolaryngol Head Neck Surg. 2001;148(2):155\u201365.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"6","key":"393_CR18","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1086\/315498","volume":"181","author":"JJ Carter","year":"2000","unstructured":"Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911\u20139.","journal-title":"J Infect Dis"},{"key":"393_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pvr.2015.06.007","volume":"1","author":"AR Giuliano","year":"2015","unstructured":"Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, et al. Seroconversion following anal and genital HPV infection in men: the HIM study. Papillomavirus Res. 2015;1:109\u201315.","journal-title":"Papillomavirus Res"},{"issue":"8","key":"393_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jama.297.8.813","volume":"297","author":"EF Dunne","year":"2007","unstructured":"Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813\u20139.","journal-title":"JAMA"},{"issue":"8","key":"393_CR21","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1158\/1055-9965.EPI-08-0151","volume":"17","author":"AR Giuliano","year":"2008","unstructured":"Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2036\u201343.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"393_CR22","doi-asserted-by":"publisher","first-page":"e531","DOI":"10.1016\/S2352-3018(21)00108-9","volume":"8","author":"F Wei","year":"2021","unstructured":"Wei F, Gaisa MM, D\u2019Souza G, Xia N, Giuliano AR, Hawes SE, et al. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29\u2009900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV. 2021;8(9):e531\u201343.","journal-title":"Lancet HIV"},{"issue":"7","key":"393_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1086\/597207","volume":"199","author":"A de Pokomandy","year":"2009","unstructured":"de Pokomandy A, Rouleau D, Ghattas G, V\u00e9zina S, Cot\u00e9 P, Macleod J, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199(7):965\u201373.","journal-title":"J Infect Dis"},{"issue":"9","key":"393_CR24","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/cid\/ciy738","volume":"68","author":"E Marra","year":"2019","unstructured":"Marra E, Kovaleva A, Bruisten SM, Vermeulen W, Boyd A, Schim van der Loeff MF. Incidence and clearance of anal high-risk human papillomavirus infections and their determinants over 5 years among human immunodeficiency virus-negative men who have sex with men. Clin Infect Dis. 2019;68(9):1556\u201365.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"393_CR25","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/infdis\/jiz623","volume":"221","author":"CJ Alberts","year":"2020","unstructured":"Alberts CJ, Heard I, Canestri A, Marchand L, Fl\u00e9jou JF, Piroth L, et al. Incidence and Clearance of Anal Human Papillomavirus (HPV)-16 and HPV-18 Infection, and Their Determinants, Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in France. J Infect Dis. 2020;221(9):1488\u201393.","journal-title":"J Infect Dis"},{"issue":"1","key":"393_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03913-5","volume":"12","author":"MG Don\u00e0","year":"2022","unstructured":"Don\u00e0 MG, Giuliani M, Rollo F, Vescio MF, Benevolo M, Giglio A, et al. Incidence and clearance of anal high-risk human papillomavirus infection and their risk factors in men who have sex with men living with HIV. Sci Rep. 2022;12(1):184.","journal-title":"Sci Rep"},{"issue":"3","key":"393_CR27","doi-asserted-by":"publisher","first-page":"e692","DOI":"10.1093\/cid\/ciac581","volume":"76","author":"F Wei","year":"2023","unstructured":"Wei F, Goodman MT, Xia N, Zhang J, Giuliano AR, D\u2019Souza G, et al. Incidence and clearance of anal human papillomavirus infection in 16 164 individuals, according to human immunodeficiency virus status, sex, and male sexuality: an international pooled analysis of 34 longitudinal studies. Clin Infect Dis. 2023;76(3):e692\u2013701.","journal-title":"Clin Infect Dis"},{"issue":"24","key":"393_CR28","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1056\/NEJMoa2201048","volume":"386","author":"JM Palefsky","year":"2022","unstructured":"Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, et al. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer. N Engl J Med. 2022;386(24):2273\u201382.","journal-title":"N Engl J Med"},{"key":"393_CR29","unstructured":"World Health Organization (WHO). Human Papillomavirus (HPV) vaccination coverage 2025 [cited 2026 Jul] [Available from: https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/human-papillomavirus-(hpv)-vaccination-coverage."},{"key":"393_CR30","unstructured":"World Health Organization (WHO). Cervical cancer screening among women aged 30-49 years, prevalence 2025 [cited 2026 Jul] [Available from: https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/prevalence-of-cervical-cancer-screening-among-women-aged-30-49-years-%28-%29."},{"key":"393_CR31","unstructured":"Serrano B, Roura E, Alemany L, de Sanjose S, Cowan M, Poljak M, et al. 2022 WHO estimates for overall and HPV-based cervical cancer screening coverage worldwide (Manuscript under review). 2022."},{"issue":"5","key":"393_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1056\/NEJMoa0909537","volume":"364","author":"AR Giuliano","year":"2011","unstructured":"Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401\u201311.","journal-title":"N Engl J Med"},{"issue":"17","key":"393_CR33","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","volume":"365","author":"JM Palefsky","year":"2011","unstructured":"Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576\u201385.","journal-title":"N Engl J Med"},{"issue":"3","key":"393_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","volume":"22","author":"SE Goldstone","year":"2022","unstructured":"Goldstone SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, Penny ME, Cabello RE, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22(3):413\u201325.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"393_CR35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/infdis\/jix105","volume":"217","author":"D Novakovic","year":"2018","unstructured":"Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208\u201312.","journal-title":"J Infect Dis"},{"issue":"1","key":"393_CR36","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","volume":"1","author":"M Brisson","year":"2016","unstructured":"Brisson M, B\u00e9nard \u00c9, Drolet M, Bogaards JA, Baussano I, V\u00e4nsk\u00e4 S, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8\u201317.","journal-title":"Lancet Public Health"},{"issue":"10","key":"393_CR37","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1002\/ijc.31231","volume":"142","author":"T Luostarinen","year":"2018","unstructured":"Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018;142(10):2186\u20137.","journal-title":"Int J Cancer"},{"issue":"14","key":"393_CR38","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","volume":"383","author":"J Lei","year":"2020","unstructured":"Lei J, Ploner A, Elfstr\u00f6m KM, Wang J, Roth A, Fang F, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340\u20138.","journal-title":"N Engl J Med"},{"issue":"12","key":"393_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050669","volume":"11","author":"M Lehtinen","year":"2021","unstructured":"Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Bly A, et al. Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. BMJ Open. 2021;11(12):e050669.","journal-title":"BMJ Open"},{"issue":"6","key":"393_CR40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/infdis\/jiaa099","volume":"222","author":"S V\u00e4nsk\u00e4","year":"2020","unstructured":"V\u00e4nsk\u00e4 S, Luostarinen T, Baussano I, Apter D, Eriksson T, Natunen K, et al. Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied. J Infect Dis. 2020;222(6):948\u201356.","journal-title":"J Infect Dis"},{"issue":"6","key":"393_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003588","volume":"18","author":"P Gray","year":"2021","unstructured":"Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, V\u00e4nsk\u00e4 S, et al. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: a cross-sectional cohort analysis following a cluster randomized trial. PLoS Med. 2021;18(6):e1003588.","journal-title":"PLoS Med"},{"key":"393_CR42","unstructured":"World Health Organization (WHO). Considerations for human papillomavirus (HPV) vaccine product choice . Geneva; 2024."},{"issue":"1-2","key":"393_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0264-410X(02)00440-1","volume":"21","author":"G Fran\u00e7ois","year":"2002","unstructured":"Fran\u00e7ois G, Hallauer J, Van Damme P. Hepatitis B vaccination: how to reach risk groups. Vaccine. 2002;21(1\u20132):1\u20134.","journal-title":"Vaccine"},{"issue":"Suppl","key":"393_CR44","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0264-410X(98)00286-2","volume":"16","author":"P Bonanni","year":"1998","unstructured":"Bonanni P. Universal hepatitis B immunization: infant, and infant plus adolescent immunization. Vaccine. 1998;16(Suppl):S17-22.","journal-title":"Vaccine"},{"issue":"7086","key":"393_CR45","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/bmj.314.7086.1033","volume":"314","author":"P Van Damme","year":"1997","unstructured":"Van Damme P, Kane M, Meheus A, Viral Hepatitis Prevention Board. Integration of hepatitis B vaccination into national immunisation programmes. BMJ. 1997;314(7086):1033\u20136.","journal-title":"BMJ"},{"issue":"Suppl 1","key":"393_CR46","first-page":"S28","volume":"42","author":"A Carter","year":"2030","unstructured":"Carter A, Msemburi W, Sim SY, Gaythorpe KAM, Lambach P, Lindstrand A, et al. Modeling the impact of vaccination for the immunization agenda 2030: deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030. Vaccine. 2030;42(Suppl 1):S28-s37.","journal-title":"Vaccine"},{"issue":"8","key":"393_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/v13081644","volume":"13","author":"M Grandahl","year":"2021","unstructured":"Grandahl M, Nev\u00e9us T. Barriers towards HPV vaccinations for boys and young men: a narrative review. Viruses. 2021;13(8):1644.","journal-title":"Viruses"},{"key":"393_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/ITT.S451659","volume":"13","author":"W Gezimu","year":"2024","unstructured":"Gezimu W, Bekele F, Bekana T, Demeke A. Males\u2019 Access to Human Papillomavirus Vaccination in Resource-Limited Settings. Immunotargets Ther. 2024;13:95\u20138.","journal-title":"Immunotargets Ther"},{"issue":"35","key":"393_CR49","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1016\/j.vaccine.2014.06.064","volume":"32","author":"JG Ogembo","year":"2014","unstructured":"Ogembo JG, Manga S, Nulah K, Foglabenchi LH, Perlman S, Wamai RG, et al. Achieving high uptake of human papillomavirus vaccine in Cameroon: lessons learned in overcoming challenges. Vaccine. 2014;32(35):4399\u2013403.","journal-title":"Vaccine"},{"issue":"1","key":"393_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22776-3","volume":"25","author":"AA Njoh","year":"2025","unstructured":"Njoh AA, Waheed DE, Kedakse T, Ebongue LJ, Kongnyuy EJ, Amani A, et al. Overcoming challenges and achieving high HPV vaccination uptake in Cameroon: lessons learned from a gender-neutral and single-dose program and community engagement. BMC Public Health. 2025;25(1):1696.","journal-title":"BMC Public Health"},{"issue":"21","key":"393_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126177","volume":"42","author":"RL Cameron","year":"2024","unstructured":"Cameron RL, Palmer TJ, Cuschieri K, Kavanagh K, Roy K. Assessing real world vaccine effectiveness: a review of Scotland\u2019s approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease. Vaccine. 2024;42(21):126177.","journal-title":"Vaccine"},{"issue":"10","key":"393_CR52","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/jech-2017-209113","volume":"71","author":"RL Cameron","year":"2017","unstructured":"Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, et al. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap. J Epidemiol Community Health. 2017;71(10):954\u201360.","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"393_CR53","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/ijc.70183","volume":"158","author":"TJ Palmer","year":"2026","unstructured":"Palmer TJ, Kavanagh K, Cuschieri K, Cameron RL, Graham C, Wilson A, et al. Sustained impact of bivalent HPV immunisation on CIN incidence over two rounds of cervical screening. Int J Cancer. 2026;158(5):1348\u201360.","journal-title":"Int J Cancer"},{"key":"393_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q2296","volume":"387","author":"K Soldan","year":"2024","unstructured":"Soldan K, Falcaro M, Sasieni P. HPV vaccination has dramatically reduced inequalities in cervical cancer, but the most deprived group remains at highest risk. BMJ. 2024;387:q2296.","journal-title":"BMJ"},{"issue":"11","key":"393_CR55","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/S1473-3099(20)30860-4","volume":"21","author":"M Drolet","year":"2021","unstructured":"Drolet M, Laprise JF, Martin D, Jit M, B\u00e9nard \u00c9, Gingras G, et al. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infect Dis. 2021;21(11):1598\u2013610.","journal-title":"Lancet Infect Dis"},{"issue":"10224","key":"393_CR56","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","volume":"395","author":"M Brisson","year":"2020","unstructured":"Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575\u201390.","journal-title":"Lancet"},{"key":"393_CR57","unstructured":"International Agency for Research on C. METHIS modelling platform."},{"key":"393_CR58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81752","author":"I Man","year":"2023","unstructured":"Man I, Georges D, Bonjour M, Baussano I. Approximating missing epidemiological data for cervical cancer through Footprinting: a case study in India. Elife. 2023. https:\/\/doi.org\/10.7554\/eLife.81752.","journal-title":"Elife"},{"key":"393_CR59","doi-asserted-by":"crossref","unstructured":"Wondimu A, Georges D, Macacu A, Wittenauer R, Fuady A, Gini A, et al. Determining context-specific economically feasible age ranges for female HPV catch-up vaccination in LMICs: a model-based health economic assessment. medRxiv. 2026:2026.03.26.26348394.","DOI":"10.64898\/2026.03.26.26348394"},{"issue":"1","key":"393_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ijc.33185","volume":"148","author":"GM Clifford","year":"2021","unstructured":"Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale. Int J Cancer. 2021;148(1):38\u201347.","journal-title":"Int J Cancer"},{"issue":"3","key":"393_CR61","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/cid\/ciad205","volume":"77","author":"AA Deshmukh","year":"2023","unstructured":"Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Clifford GM. Human papillomavirus-associated anal cancer incidence and burden among US men, according to sexual orientation, human immunodeficiency virus status, and age. Clin Infect Dis. 2023;77(3):419\u201324.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"393_CR62","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/ijc.34269","volume":"152","author":"AA Deshmukh","year":"2023","unstructured":"Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Ferlay J, Bray F, et al. Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis. Int J Cancer. 2023;152(3):417\u201328.","journal-title":"Int J Cancer"},{"issue":"4","key":"393_CR63","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S2352-3018(25)00011-6","volume":"12","author":"A Uusk\u00fcla","year":"2025","unstructured":"Uusk\u00fcla A, Tisler A, DeHovitz J, Murenzi G, Castle PE, Clifford G. Prevention and control of HPV-related cancers in people living with HIV. Lancet HIV. 2025;12(4):e293\u2013302.","journal-title":"Lancet HIV"},{"issue":"2","key":"393_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","volume":"18","author":"C Lin","year":"2018","unstructured":"Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(2):198\u2013206.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"393_CR65","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/infdis\/jiac108","volume":"227","author":"F Wei","year":"2023","unstructured":"Wei F, Xia N, Ocampo R, Goodman MT, Hessol NA, Grinsztejn B, et al. Age-specific prevalence of anal and cervical human papillomavirus infection and high-grade lesions in 11 177 women by human immunodeficiency virus status: a collaborative pooled analysis of 26 studies. J Infect Dis. 2023;227(4):488\u201397.","journal-title":"J Infect Dis"},{"issue":"11","key":"393_CR66","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/infdis\/jiad183","volume":"228","author":"F Wei","year":"2023","unstructured":"Wei F, Alberts CJ, Albuquerque A, Clifford GM. Impact of human papillomavirus vaccine against anal human papillomavirus infection, anal intraepithelial neoplasia, and recurrence of anal intraepithelial neoplasia: a systematic review and meta-analysis. J Infect Dis. 2023;228(11):1496\u2013504.","journal-title":"J Infect Dis"},{"issue":"3","key":"393_CR67","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/infdis\/jiae394","volume":"231","author":"CL DeSisto","year":"2025","unstructured":"DeSisto CL, Winer RL, Querec TD, Dada D, Pathela P, Asbel L, et al. Vaccine Effectiveness Against Anal HPV Among Men Who Have Sex With Men Aged 18\u201345 Years Attending Sexual Health Clinics in 3 United States Cities, 2018\u20132023. J Infect Dis. 2025;231(3):751\u201361.","journal-title":"J Infect Dis"},{"issue":"9","key":"393_CR68","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1038\/bjc.2015.90","volume":"112","author":"EM King","year":"2015","unstructured":"King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, et al. Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. Br J Cancer. 2015;112(9):1585\u201393.","journal-title":"Br J Cancer"},{"issue":"10","key":"393_CR69","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/ijc.34850","volume":"154","author":"EA Stier","year":"2024","unstructured":"Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, et al. International anal neoplasia society\u2019s consensus guidelines for anal cancer screening. Int J Cancer. 2024;154(10):1694\u2013702.","journal-title":"Int J Cancer"},{"key":"393_CR70","doi-asserted-by":"publisher","first-page":"107327482614663","DOI":"10.1177\/10732748261466365","volume":"33","author":"AN Burchell","year":"2026","unstructured":"Burchell AN, Grennan T, Fahim C, Gaid D, Odhiambo AJ, Leung SOA. Application of the Cascade of Care Framework to Guide Evidence-Informed Implementation of Anal Cancer Screening Guidelines. Cancer Control. 2026;33:10732748261466364.","journal-title":"Cancer Control"},{"issue":"8","key":"393_CR71","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/jnci\/djae094","volume":"116","author":"SH Rim","year":"2024","unstructured":"Rim SH, Beer L, Saraiya M, Tie Y, Yuan X, Weiser J. Prevalence of anal cytology screening among persons with HIV and lack of access to high-resolution anoscopy at HIV care facilities. J Natl Cancer Inst. 2024;116(8):1319\u201332.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"393_CR72","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1097\/QAD.0000000000002948","volume":"35","author":"R Silvera","year":"2021","unstructured":"Silvera R, Martinson T, Gaisa MM, Liu Y, Deshmukh AA, Sigel K. The other side of screening: predictors of treatment and follow-up for anal precancers in a large health system. AIDS. 2021;35(13):2157\u201362.","journal-title":"AIDS"},{"issue":"1","key":"393_CR73","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s43058-023-00480-w","volume":"4","author":"C Fahim","year":"2023","unstructured":"Fahim C, Courvoisier M, Somani N, De Matas F, Straus SE. Creation of a theoretically rooted workbook to support implementers in the practice of knowledge translation. Implement Sci Commun. 2023;4(1):99.","journal-title":"Implement Sci Commun"},{"key":"393_CR74","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fpubh.2019.00158","volume":"7","author":"ME Fernandez","year":"2019","unstructured":"Fernandez ME, Ten Hoor GA, van Lieshout S, Rodriguez SA, Beidas RS, Parcel G, et al. Implementation Mapping: Using Intervention Mapping to Develop Implementation Strategies. Front Public Health. 2019;7:158.","journal-title":"Front Public Health"},{"issue":"1","key":"393_CR75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13012-017-0605-9","volume":"12","author":"L Atkins","year":"2017","unstructured":"Atkins L, Francis J, Islam R, O\u2019Connor D, Patey A, Ivers N, et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implement Sci. 2017;12(1):77.","journal-title":"Implement Sci"},{"key":"393_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112643","volume":"244","author":"M Gaspar","year":"2020","unstructured":"Gaspar M, Rosenes R, Burchell AN, Grennan T, Salit I, Grace D. Diagnosing uncertainty: the challenges of implementing medical screening programs for minority sub-populations in Canada. Soc Sci Med. 2020;244:112643.","journal-title":"Soc Sci Med"},{"issue":"2","key":"393_CR77","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/09540121.2021.1883512","volume":"34","author":"RT Higashi","year":"2022","unstructured":"Higashi RT, Rodriguez SA, Betts AC, Tiro JA, Luque AE, Rivera R, et al. Anal cancer screening among women with HIV: provider experiences and system-level challenges. AIDS Care. 2022;34(2):220\u20136.","journal-title":"AIDS Care"},{"key":"393_CR78","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12889-015-1430-1","volume":"15","author":"JJ Ong","year":"2015","unstructured":"Ong JJ, Temple-Smith M, Chen M, Walker S, Grulich A, Hoy J, et al. Why are we not screening for anal cancer routinely - HIV physicians\u2019 perspectives on anal cancer and its screening in HIV-positive men who have sex with men: a qualitative study. BMC Public Health. 2015;15:67.","journal-title":"BMC Public Health"},{"issue":"3","key":"393_CR79","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/QAI.0000000000002335","volume":"84","author":"JL Gillis","year":"2020","unstructured":"Gillis JL, Grennan T, Grewal R, Ogilvie G, Gaspar M, Grace D, et al. Racial disparities in anal cancer screening among men living with HIV: findings from a clinical cohort study. J Acquir Immune Defic Syndr. 2020;84(3):295\u2013303.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"393_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14471-4","volume":"22","author":"JL Gillis","year":"2022","unstructured":"Gillis JL, Grennan T, Grewal R, Ogilvie G, Gaspar M, Grace D, et al. Influence of previous experience with and beliefs regarding anal cancer screening on willingness to be screened among men living with HIV. BMC Public Health. 2022;22(1):2444.","journal-title":"BMC Public Health"},{"issue":"1","key":"393_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16847-6","volume":"23","author":"G Cruz","year":"2023","unstructured":"Cruz G, Ramos-Cartagena JM, Torres-Russe JL, Col\u00f3n-L\u00f3pez V, Ortiz-Ortiz KJ, Pericchi L, et al. Barriers and facilitators to anal cancer screening among people living with HIV in Puerto Rico. BMC Public Health. 2023;23(1):1940.","journal-title":"BMC Public Health"},{"issue":"11","key":"393_CR82","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1089\/apc.2024.0171","volume":"38","author":"MC Geba","year":"2024","unstructured":"Geba MC, Kalluri D, Mitchell EM, Flickinger T, Cardenas B, Dillingham R, et al. Identifying motivators, facilitators, and barriers to engagement and retention in anal cancer screening among men and women with HIV in one Ryan White HIV\/AIDS clinic. AIDS Patient Care STDS. 2024;38(11):530\u20138.","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"393_CR83","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/LGT.0000000000000598","volume":"25","author":"AP Ortiz","year":"2021","unstructured":"Ortiz AP, Garc\u00eda-Camacho SI, Ramos-Cartagena JM, Col\u00f3n-L\u00f3pez V, Estremera-Rodr\u00edguez LM, Berr\u00edos-Toledo KM, et al. Knowledge, attitudes, and experiences of anal cancer and anal cancer screening among a clinical sample of Hispanic women. J Low Genit Tract Dis. 2021;25(2):98\u2013105.","journal-title":"J Low Genit Tract Dis"},{"issue":"11","key":"393_CR84","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/ijc.34199","volume":"151","author":"MA Clarke","year":"2022","unstructured":"Clarke MA, Deshmukh AA, Suk R, Roberts J, Gilson R, Jay N, et al. A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups. Int J Cancer. 2022;151(11):1889\u2013901.","journal-title":"Int J Cancer"}],"container-title":["BMC Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12919-026-00393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12919-026-00393-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12919-026-00393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:03:17Z","timestamp":1790028197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12919-026-00393-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":84,"journal-issue":{"issue":"S33","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1186\/s12919-026-00393-1","relation":{},"ISSN":["1753-6561"],"issn-type":[{"value":"1753-6561","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"22 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HPV Prevention and Control Board meetings are invitation-only meetings. All participants accepted the invitation and attended the meeting out of their free will. The HPV Prevention and Control Board asked the participants to fill out a \u2018consent form\u2019, agreeing that the videos and photos of the meetings can be published online. The speakers are also asked to fill out a consent form to agree\/disagree that their presentation can be published on the website, included in the meeting report or used for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LB research department has received unrestricted grants from MSD. A.R.G reports receiving funds from Merck&CO, Inc for her role on scientific advisory committees. In addition, A.R.G\u2019s institution receives funds for research form Merck&CO, Inc. J.M.P declares receiving consultancy fees from Merck, Roche Diagnostics and Cote Holdings. J.M.P also declares being a stock shareholder of Virion Therapeutics. P.R declaes a clinical mandate from Belgian Foundation against cancer (Stichting tegen Kanker) and speaker and consultancy fees from MSD Belgium. M.B.Y. is an employee of P95 Clinical & Epidemiology Services, which is contracted by vaccine-producing companies, including Merck and GSK, for consultancy services. A.V. is cofounder and former board member of Novosanis, a spin-off company of the University of Antwerp, and was minority shareholder until January 2019. The University of Antwerp obtained unrestricted educational grants from Becton Dickinson, Hologic, and Roche. Where authors are identified as personnel of the International Agency for Research on Cancer\/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer \/World Health Organization. All other authors declares no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"36"}}